BioStem Technologies Expands Product Access in Medicaid

Core Insights - BioStem Technologies, Inc. has announced the inclusion of its products VENDAJE and VENDAJE AC in Florida Medicaid's list of covered skin substitutes, marking a significant milestone in its national reimbursement strategy [1][2][3] Group 1: Company Developments - The addition of Florida Medicaid coverage enhances BioStem's mission to provide high-quality wound care, significantly increasing its addressable patient base in one of the largest Medicaid markets in the U.S. [3] - BioStem's advanced wound care market is estimated to exceed $11 billion annually in the U.S., with over 70 million Americans enrolled in Medicaid, including approximately 7 million aged 65 and older [3] Group 2: Product Information - VENDAJE and VENDAJE AC are placental-derived, minimally manipulated dehydrated tissue allografts designed for soft tissue wound protection, utilizing the proprietary BioREtain technology to optimize the retention of extracellular matrix scaffolding [5][6] Group 3: Distribution Strategy - BioStem is actively seeking qualified regional distributors and wound care organizations to represent the VENDAJE portfolio in Florida and other covered states [4]